Previous Close | 0.1300 |
Open | 0.0400 |
Bid | 0.0000 |
Ask | 0.2200 |
Strike | 40.00 |
Expire Date | 2024-10-18 |
Day's Range | 0.0400 - 0.1300 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX).
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
WILMINGTON, Del., May 02, 2024--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL).